Indeed, since T2DM patients with insulin therapy generally have a longer duration of diabetes, undesirable glycemic control, and a higher risk of cardiovascular comorbidities and are often treated with insulin in combination with other oral antidiabetic therapies, these factors may be the major confounders in assessing the association between insulin use and adverse outcomes. This evidence concerns the gene INS and type 2 diabetes mellitus.